Aldosterone blockade in patients with heart failure and a reduced left ventricular ejection fraction.

نویسنده

  • Bertram Pitt
چکیده

Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), b-adrenergic receptor blockers (BBs), and aldosterone blockers (ABs) have been shown to be effective in reducing cardiovascular mortality and the need for hospitalizations for heart failure (HF) in patients with chronic HF and a reduced left ventricular ejection fraction (HFREF) and in patients with HFREF post-myocardial infarction (MI). The use of ACEIs, ARBs, and BBs in appropriate patients in clinical practice has, however, been far greater than for ABs. There are probably a number of reasons for this apparent gap in the application of ABs to clinical practice despite their class 1 indication for patients with severe chronic HFREF and in patients with HF post-MI. In part, the greater use of ACEIs, ARBs, and BBs can be attributed to the greater number of available agents in each of these classes, a greater number of large-scale randomized trials demonstrating their effectiveness in comparison with ABs, and the fact that the available ABs are generic or soon to be generic and hence have not been the focus of intensive marketing in comparison with the newer ARBs and BBs. Another explanation for the relatively low use of ABs in appropriate patients with chronic HFREF in clinical practice relates to the risk of hyperkalaemia and its consequences. In a recent review of the effect of eplerenone on serum potassium in the EPHESUS trial, it was pointed out that despite the occurrence of hyperkalaemia there was not a single death attributable to hyperkalaemia either in EPHESUS or RALES. It should, however, be emphasized that it is necessary to select patients carefully on the basis of their renal function, to monitor serum potassium, and to adjust the dose of the AB accordingly if hyperkalaemia is to be avoided. In patients with an estimated glomerular filtration rate (eGFR) .60 mL/min/1.73 m, there was no significant increase in hyperkalaemia in EPHESUS, whereas in those with an eGFR 60 mL/min/1.73 m2 in whom the risk of hyperkalaemia is increased, serum potassium should be monitored closely over the long term. The mechanisms responsible for the beneficial effects of ABs in patients with HFREF continue to evolve but include: an increase in antioxidant reserves and a decrease in oxygen free radical formation; an increase in the availability of nitric oxide and an improvement in endothelial function; a decrease in vascular and myocardial fibrosis, hypertrophy, and remodelling; a decrease in sympathetic nervous system activation; a decrease in myocardial calcium channel expression; a decrease in myocardial apoptosis; as well as an increase in sodium excretion with a concomitant decrease in plasma volume. The recent meta-analysis by Ezekowitz and McAlister of 19 randomized trials comprising 10 807 patients with either chronic HFREF or HF post-MI randomized to an AB (spironolactone, eplerenone, or canreonate) or placebo focuses attention on the role of ABs in patients with HFREF and shows a 20% reduction in all-cause mortality [95% confidence interval (CI) 0.74–0.87] in patients randomized to an AB. Although the RALES and EPHESUS trials supplied the overwhelming majority of the evidence supporting the effectiveness of AB in these patient populations, the results of the remaining relatively smaller trials are consistent with the results of the larger trials. These beneficial results were associated with an absolute 2.9% increase in hyperkalaemia in patients randomized to an AB. However, the three trials with the highest incidence of hyperkalaemia were dose-finding trials in which doses of spironolactone or eplerenone .50 mg/day were used. They also point out that whereas ABs have shown a significant reduction in all-cause mortality in patients with HFREF when added to an ACEI, ARBs have not. In recent meta-analyses of ACEIs, ARBs, and their combination in patients with HFREF, there was no apparent benefit of adding an ARB to an ACEI, whereas the combination was associated with a significant increase

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The Relation between Left Ventricular Function and Serum Ferritin in Major Β-Thalassemia

Abstract Objective Cardiac dysfunction is a major cause of death in patients with beta thalassemia. In these patients, repeated blood transfusion, ineffective erythropoiesis and increased gastrointestinal iron absorption lead to iron overload in the body and this induced heart failure. Left ventricular ejection fraction was measured in major beta thalassemia (β-Th) patients to detect the rela...

متن کامل

Clinical Medicine Insights: Therapeutics

Aldosterone blockade has been shown to be effective in reducing total mortality in patients with severe heart failure due to systolic left ventricular dysfunction and in patients with heart failure post myocardial infarction. Increasing evidence suggests that aldosterone blockade alone and or in conjunction with an angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker ...

متن کامل

Effect of Exercise Training on Heart Rate Variability in Patients with Heart Failure After Percutaneous Coronary Intervention

Background: This study aims to evaluate the effect of exercise training on heart rate variability (HRV) and to determine the correlation between parameters of HRV and the ejection fraction in patients with heart failure after percutaneous coronary intervention.Material and Methods: Fifty patients with left ventricular ejection fraction ≤ 40% undergone percutaneous coronary intervention were r...

متن کامل

Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.

CONTEXT Aldosterone blockade has been used to treat acute myocardial infarction (MI) and chronic heart failure. OBJECTIVE The aim of this study is to summarize the evidence on the efficacy of spironolactone (SP), eplerenone (EP), or canrenoate (CAN) in patients with left ventricular dysfunction. DATA SOURCES A search of multiple electronic databases until June 2008 was supplemented by hand ...

متن کامل

Evaluation of heart disease in patients with beta-thalessemia major referred to Shahid Madanni Hospital in Khorram Abad in 2003

Background: Patients with beta-thalessemia major present with severe anemia and need continous transfusion therapy. An important complication of beta-thalessemia major is iron deposition in cardiac tissue, resulting in fibrosis and dysfunction. Cardiac involvement is the major cause of death in beta-thalessemia major. The purpose of this study was to assess cardiac disease patients with bet...

متن کامل

Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients WithHeartFailureWithPreservedEjectionFraction

HEART FAILURE (HF) WITH preserved ejection fraction (EF) accounts for more than 50% of the total HF population. Community-based cohort studies have shown that mortality rates are similar in HF with preserved EF compared with HF with reduced EF, but data from large clinical trials point toward a better outcome in HF with preserved EF. This may indicate that comorbidities that are typically exclu...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • European heart journal

دوره 30 4  شماره 

صفحات  -

تاریخ انتشار 2009